1. Companies

  2. MiMedx Group

MiMedx Group

MiMedx Group

Launch date
Employees
501-1000 people
Market cap
€830m
Enterprise valuation
€785m (Public information from Sep 2024)
Marietta Georgia (HQ)
http://mimedx.com
https://twitter.com/mimedxhttps://www.facebook.com/mimedxhttps://www.linkedin.com/company/mimedx

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues248m259m268m321m343m382m439m
% growth(17 %)4 %4 %20 %7 %11 %15 %
EBITDA(37.5m)<1m(20.9m)40.5m69.0m87.8m112m
% EBITDA margin(15 %)-(8 %)13 %20 %23 %26 %
Profit(49.3m)(10.3m)(30.2m)67.4m42.2m48.0m67.4m
% profit margin(20 %)(4 %)(11 %)21 %12 %13 %15 %
EV / revenue3.9x2.6x1.2x3.2x2.9x2.6x2.3x
EV / EBITDA-26.0x3766.8x-15.1x25.2x14.6x11.4x8.9x
R&D budget11.7m17.3m22.8m12.7m---
R&D % of revenue5 %7 %9 %4 %---
    • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$675k

Early VC
N/A

$2.1m

Post IPO Equity
N/A

$950k

Early VC
N/A

$34.0m

Post IPO Equity
N/A

$500k

Grant
N/A

£1.0m

Seed

$75.0m

Post IPO Debt
N/A

N/A

-
*

$4.6m

Grant
Total Funding€7.3m

Related Content

Recent News about MiMedx Group

Edit
More about MiMedx Groupinfo icon
Edit

MIMEDX® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by MiMedx Group

Edit
Stability Biologics
Stability Biologics
ACQUISITION by MiMedx Group Jan 2016